Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Thomas, George V, Tran, Chris, Mellinghoff, Ingo K, Welsbie, Derek S, Chan, Emily, Fueger, Barbara, Czernin, Johannes, Sawyers, Charles L·2006·Nature Medicine
DOI 10.1038/nm1337

Cited by (605)

Items 501–600 of 605

  1. Papillary Renal Cell Carcinoma: Current Evidence and Future Directions
    Albert Jang, Charbel S. Hobeika, Shilpa Gupta · 2024 · Kidney Cancer
  2. Folliculin Deficient Renal Cancer Cells Show Higher Radiosensitivity through Autophagic Cell Death
    Qi Zhang, Shuhui Si, Sue Schoen, Xunbo Jin, Jindong Chen, Guan Wu · 2014 · The Journal of Urology
  3. Stability of ready-to-use temsirolimus infusion solution (100 mg/L) in polypropylene containers under different storage conditions
    Sylvain Poujol, Françoise Bressolle, Isabelle Solassol, Frédéric Pinguet · 2012 · Annales Pharmaceutiques Françaises
  4. The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition
    Pedro Coelho Barata, Moshe Chaim Ornstein, Jorge Alberto Garcia · 2017 · Journal of Kidney Cancer and VHL
  5. HCS strategy targeting dysregulation of the VHL/HIF pathway for drug discovery
    Bastien Cautain, Nuria de Pedro, María Muñoz de Escalona, José Rubén Tormo, Olga Genilloud, Francisca Vicente · 2013 · Advances in Bioscience and Biotechnology
  6. Estrategias actuales en el tratamiento del carcinoma de células renales: fármacos dirigidos a dianas moleculares
    José Manuel Trigo, Joaquim Bellmunt B · 2008 · Medicina Clínica
  7. Molecular-targeted Therapy for Renal Cell Carcinoma
    Robert John Amato, Mika Stepankiw, Nwabugwu S. Ochuwa · 2013 · Elsevier eBooks
  8. Mitochondrial Translation Inhibition Uncovers a Critical Metabolic–Epigenetic Interface in Renal Cell Carcinoma
    Kazumi H Eckenstein, Beyza Cengiz, Matthew E.K. Chang, Jessie May Cartier, Mark R. Flory, GEORGE V. THOMAS · 2025 · Metabolites
  9. The VHL-HIF Signaling in Renal Cell Carcinoma: Promises and Pitfalls
    Christudas Morais, David W., Carla Glenda · 2012 · InTech eBooks
  10. The mTOR Complexes in Cancer Cell Metabolism
    Thomas P. Lynch, Joseph Gennaro Moloughney, Estela Jacinto · 2016 · Cancer drug discovery and develogment/Cancer drug discovery and development
  11. Involvement of mTOR signaling in physiopathology and its potential therapeutic interventions
    Irene Martín-Bocanegra, Thaissa L Horne, Belén Maqueda-Hernández, Elena Navarro‐Villarán, Jordi Muntané · 2023 · Redox Experimental Medicine
  12. Role of Systemic Therapy in Localized Renal Cell Carcinoma: Where Do We Stand and Where Are We Heading?
    Deepa Raghavan, Viktoriya Gibatova, Nikhil Vojjala, Nagaishwarya Moka, Aihua Edward Yen · 2025 · Cancers
  13. Molecular Biology of Kidney Cancer
    William G. Kaelin · 2011 · Springer eBooks
  14. Temisorlimus in the treatment of advanced renal cell carcinoma
    Bernard J. Escudier · 2007 · Oncology Reviews
  15. Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: moving to guidelines
    Sebastién J. Hotte, Anil Kapoor · 2012 · Canadian Urological Association Journal
  16. Case Report: Late simultaneous metastasis of renal clear cell carcinoma to the ampulla and breast
    Guofeng Dai, Shuya Li, Lei Sun, Gangpu Wang · 2025 · Frontiers in Oncology
  17. Role of mTORC1 signaling in postnatal microglia activation preceding neurodegeneration in a mouse model for Niemann-Pick disease Type C
    Caroline E. Murray, David S. Betancourt-Trompa, Michael S. Martinez, Julia M. Carson, Lindsay J. Walsh, Will C. Remillard, Kayla B. Fordyce, Rohan Reddy, Ileana Soto · 2025 · PLoS ONE
  18. Beyond mTOR: Unraveling the Complex Pathophysiology and Signaling Pathways in Focal Cortical Dysplasia
    Kang Yang, Yanqing He, Jingxing Leng, Tao Lu, Ying Wang, Kang Xie, Tao Song, Zhong Chen, Longbo Zhang · 2025 · Molecular Neurobiology
  19. Hypoxia‐Inducible Factors as Guardians of Cancer Stem Cell Fate: Implications for Novel Therapies
    Qamar Abuhassan, Hamzeh J. Al‐Ameer, Hani Moslem Ahmed, Jasur Alimdjanovich Rizaev, Azizbek Togaev, Rasim Mahdi Salih, Mohaned Adil · 2026 · IUBMB Life
  20. Molecular Targeted Anticancer Drugs
    Kyu‐Won Kim, Jae Kyung Roh, Hee‐Jun Wee, Chan Kim · 2016 · Springer eBooks
  21. Molecular Biology of Clear Cell Renal Carcinoma
    William G. Kaelin · 2012 · Springer eBooks
  22. Molecular Pathogenesis of Renal Cell Carcinoma: A Review
    Israel Gomy, Wilson Arajo Silva · 2012 · InTech eBooks
  23. Analysis of Molecular Cytogenetic Changes in Metastatic Renal Cell Carcinoma in the Setting of Everolimus Treatment: A Pilot Project
    Imogen Rose Caldwell, Paul Oei, Daniel Ng, Beth Caudwell, Peter C.C. Fong, Reuben James Broom · 2014 · Clinical Genitourinary Cancer
  24. Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma
    Giuseppe Lombardi, Fable Zustovich, Nicoletto, Pastorelli, Dal Bianco, Zorzi, Zagonel · 2011 · Research and Reports in Urology
  25. Nontuberculous mycobacterial infection after therapy with temsirolimus for metastatic renal cell carcinoma
    Tomáš Büchler, J Homolka, Pavel Fencl, Blanka Rosová, Vladislav Hytych, Jitka Abrahámová · 2013 · Tumori Journal
  26. Hyperpolarized 13C magnetic resonance imaging, using metabolic imaging to improve the detection and management of prostate, bladder, and kidney urologic malignancies
    Vijay Vishwanath, Dirk Mayer, De‐Xue Fu, Amelia M. Wnorowski, Mohummad Minhaj Siddiqui · 2018 · Translational Andrology and Urology
  27. The Role of Target of Rapamycin Signaling in Tuberous Sclerosis Complex
    Brendan D. Manning · 2010
  28. Recent advances in molecularly targeted therapy in advanced renal cell carcinoma
    Jaeyeon Kim, Brian I. Rini · 2009 · Therapy
  29. Metastatic Renal Cell Carcinoma: Role of Mammalian Target of Rapamycin Inhibitors
    Ronald M. Bukowski · 2007 · Clinical Genitourinary Cancer
  30. In vitro analysis of potential anticancer effects associated with watercress
    Breeze E. Cavell · 2012 · ePrints Soton (University of Southampton)
  31. Synthetic Lethality with Homologous Recombination Repair Defects
    Helen E. Bryant, Sydney Shall · 2015 · Cancer drug discovery and develogment/Cancer drug discovery and development
  32. TOR: A Conserved Nutrient-Sensing Pathway that Determines Life-Span Across Species
    Pankaj Kapahi, Lutz Kockel · 2010 · Elsevier eBooks
  33. Effects of Molecularly Targeting Hypoxia in Oncology
    Giammaria Fiorentini, Camillo Aliberti, Giorgio Benea, Francesco Montagnani, Andrea Mambrini, Pier Luigi Ballardini, Maurizio Cantore, Stefano Guadagni · 2009 · Springer eBooks
  34. The Molecular Biology of Kidney Cancer and Its Clinical Translation into Treatment Strategies
    William G. Kaelin, Daniel J. George · 2009 · Humana Press eBooks
  35. Unraveling the Role of Hypoxia-Inducible Factor in Renal Cell Carcinoma: A Biological and Therapeutic Perspective
    Sumanta Kumar Pal, Robert A. Figlin · 2011 · Cancer Discovery
  36. Temsirolimus: Safety and Efficacy in the Treatment of Renal Cell Carcinoma
    M. Hammad Ather and Syed M. Nazim · 2011 · Clinical Medicine Reviews in Oncology
  37. Targeted Therapeutics in Cancer Treatment
    Colin D. Weekes, Manuel M. Hidalgo · 2007 · Elsevier eBooks
  38. Profiling mTOR Pathway in Neuroendocrine Tumors
    Sara Cingarlini, Maria Bonomi, Chiara Trentin, Vincenzo Corbo, Aldo Scarpa, Giampaolo Tortora · 2014 · Springer eBooks
  39. Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications
    Jehonathan H. Pinthus, Kaitlyn F. Whelan, Daniel Gallino, Jian-Ping Lu, Nathan Rothschild · 2013 · Canadian Urological Association Journal
  40. Analysis of expression pattern of proteins associated with AKT/mTOR signaling pathway in kidney cancer development
    Ritesh Satardey, Ravi Yadav, Madhusudan Das, Dilip Kumar Pal · 2022 · Annals of Medical Science and Research
  41. The PI3K Pathway in Colorectal Cancers
    Jihye Yun, George Poulogiannis, Evan T. Brower, Samuel Jacob Klempner, Lewis C. Cantley · 2013 · Springer eBooks
  42. The Role of mTOR Inhibitors and PI3K Pathway Blockade in Renal Cell Cancer
    Tanya Barauskas Dorff, Philip C. Mack · 2015 · Springer eBooks
  43. Metabolic Shunt Pathways, Carcinoma, and mTOR
    Norisuke Shibuya, Ken-ichi Inoue, Keiichi Kubota · 2016 · Elsevier eBooks
  44. Sunitinib: An Unusual Cause of Pneumothorax in a Patient With Metastatic Chromophobe Renal Cell Carcinoma
    Nedal Bukhari, Suha Albadr, Manal Alnaimi, Faisal Azam · 2020 · Cureus
  45. Everolimus-related unilateral abdominal lymphedema in a renal cancer patient
    Jana Halámková, Tomáš Kazda, Dagmar Adámková Krákorová, Sylva Rybníčková, Igor Kišš, Regina Demlová · 2020 · Medicine
  46. Concomitant Drug Treatment and Elimination in the RCC-affected Kidneys: Can We Kill Two Birds with One Stone?
    Muhammad Bilal Ahmed, Salman Ul Islam, Young Sup Lee · 2020 · Current Drug Metabolism
  47. Hypoxic Response and Associated Diseases
    Emily Flashman, Christoph Loenarz, Christopher John Schofield · 2008 · Wiley eBooks
  48. Exploitation of Aberrant Signalling Pathways as Useful Targets for Renal Clear Cell Carcinoma Therapy
    Carol O'Callaghan, Orla Patricia · 2011 · InTech eBooks
  49. HIF‐1 Inhibitors for Cancer Therapy
    Annamaria Rapisarda, Giovanni Melillo · 2010 · Wiley eBooks
  50. Everolimus: Emerging Evidence of its Therapeutic Impact in Patients with Advanced Renal Cell Carcinoma
    Daniel C. Cho · 2010 · Clinical Medicine Reviews in Oncology
  51. Translation molekularer Zusammenhänge in die klinische Anwendung
    Rainer Kuefer, Michael E. Autenrieth, Kathleen Herkommer, P. Blum, Axel S. Merseburger, M. Hofer, Ludwig J. Rinnab, Jürgen E. Gschwend, Mark Ringhoffer · 2006 · Der Urologe
  52. Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University Curriculum vitae and Bibliography
    Ingo K. Mellinghoff · 2014
  53. Targeted Therapeutics in Cancer Treatment
    Colin D. Weekes, Manuel M. Hidalgo · 2010 · Springer eBooks
  54. Mammalian Target of Rapamycin in Renal Cell Carcinoma
    Eric Jonasch, Michel Choueiri · 2012 · Humana Press eBooks
  55. Radiotherapy in non-small cell lung cancer : does PET make the difference?
    Angela A.W. van Baardwijk · 2008
  56. Cellular adaptation to hypoxia and reoxygenation through gene specific mRNA translation
    Michaël G. Magagnin · 2008
  57. A Role For Lipid Rafts In Egfr Tki Resistance In Breast Cancer
    Mary E. Irwin · 2010 · Human Biology
  58. [Molecular biology of renal cancer: bases for genetic directed therapy in advanced disease].
    Pablo Maroto, Elena Cillán Narvaez · 2013 · PubMed
  59. Optimierung der Therapie des metastasierten Mammakarzinoms unter besonderer Berücksichtigung des Pi3K/Akt/mTOR-Signaltransduktionswegs
    Jan Eucker · 2013 · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver
  60. Intracellular Signal Transduction Cascades
    David J. Matthews, Mary E. Gerritsen · 2010
  61. mTOR inhibition as a therapeutic strategy in tuberous sclerosis or sporadic lymphangioleiomyomatosis
    D. M. Davies · 2011 · ORCA Online Research @Cardiff (Cardiff University)
  62. Targeting cancer with reovirus.
    Charles Comins · 2015 · Surrey Research Insight Open Access (The University of Surrey)
  63. Everolimus for renal cell carcinoma: predictive factors for response and future directions
    Guru Sonpavde, Thomas E. Hutson · 2009 · Medical Oncology
  64. Nuevas terapias de diana celular: indicaciones, resultados y tolerabilidad
    Joaquim Bellmunt B, Antoni Gelabert-Más · 2009 · Actas Urológicas Españolas
  65. Prerequisite Genetic Traits for Metastasis
    D. Faingold, Dawn S. Russell-Hermanns, Silvin Bakalian · 2013 · Springer eBooks
  66. The Role of mTOR Inhibitors and P13K Pathway Blockade in RCC
    Michel Choueiri, Philip C. Mack · 2011 · Springer eBooks
  67. Developments in the Management of Genitourinary Malignancies: Prostate Cancer and Renal Cell Carcinoma
    Charles J. Ryan · 2009 · Humana Press eBooks
  68. factor-2 in clear cell renal carcinoma
    Hyesik Kong, Sunmin Lee, Kristin E. Beebe, Bradley T. Scroggins, Gopal Nand Gupta, Yunjin Jung, Jane B. Trepel, Leonard Μ. Neckers · 2010
  69. Cell Death Induction by Targeting Tumor Metabolism
    Karin von Schwarzenberg · 2015 · InTech eBooks
  70. [Advanced research of mTOR and lung carcinoid tumors].
    Zixuan Zhang, Mengzhao Wang · 2013 · Europe PMC (PubMed Central)
  71. M-TOR inhibitors in the treatment of advanced renal cell carcinoma
    Rafał Stec, Michał Ma̧czewski, Marta Smoter, Lubomir Bodnar, Cezary A. Szczylik · 2011 · Współczesna Onkologia
  72. Optimal Use of Imaging to Guide Treatment Decisions for Kidney Cancer
    Walter Michael Stadler · 2012 · American Society of Clinical Oncology Educational Book
  73. The Evolving Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in Renal Cell Carcinoma
    Carlyn Rose C. Tan, Robert A. Figlin, Andrew Eugene Hendifar · 2015 · Springer eBooks
  74. Renal Cell Carcinoma: From Molecular Biology to Targeted Therapies
    Chiara Paglino, Laura Cosmai, Palma Giglione, Camillo Porta · 2015 · Springer eBooks
  75. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer
    Novartis Medal Lecture · 2011
  76. PET-CT, Bio-imaging for Predicting Prognosis and Response to Chemotherapy in Patients with Lung Cancer
    Kyoichi Kaira · 2017 · Springer eBooks
  77. Identifying novel genes involved in amino acid sensing
    Margaret Dayhoff-Brannigan · 2014
  78. Ocena potencjału terapeutycznego Temsirolimusu w zaawansowanym stadium renal cell carcinoma
    Wiktoria Maria Suchorska, Mikołaj Nowak · 2017 · Letters in Oncology Science
  79. Resistance of renal cell carcinoma to targeted therapy
    Retnagowri Rajandram, Teng Aik Ong, Marniza Bte Saad · 2014
  80. ISOLATION AND CHARACTERISATION OF RAPAMYCIN, TEMSIROLIMUS REGIO ISOMER (MONOESTER) AND TEMSIROLIMUS DIESTER IN TEMSIROLIMUS DRUG
    G. Sravan Kumar Reddy, Chava Venkata Nageswara Rao · 2019 · International Journal of Pharmacy and Pharmaceutical Sciences
  81. Experimental Design in Signal Transduction
    Weimin Gao, Meghan M. Cromie, Qian Wang, Zhongwei Liu, Song Tang, Julie Vrana Miller · 2019
  82. Inhibition of compensatory survival and proliferative pathway activation induced by mTOR inhibition in renal cell carcinoma
    Sean T. Bailey · 2019 · Carolina Digital Repository (University of North Carolina at Chapel Hill)
  83. Defining the Role of Secondary DNA Structures and Transcription Factors on the Transcriptional Control of the HIF-1alpha and VEGF Promoters
    Diana J. Uribe · 2011 · UA Campus Repository (The University of Arizona)
  84. Modulation of Protein Stability: Targeting the VHL Pathway
    William Y. Kim, William G. Kaelin · 2009 · Springer eBooks
  85. Molecular Therapies
    Camille N. Abboud · 2010 · Humana Press eBooks
  86. Nuevas terapias de diana celular: indicaciones, resultados y tolerabilidad
    Joaquim Bellmunt B, Antoni Gelabert-Más · 2009 · Actas Urológicas Españolas
  87. WITHDRAWN: Pomegranate extract inhibits EMT in clear cell renal cell carcinoma in a NF-κB and JNK dependent manner
    Jiabin An, Yanchuan Guo, Ting Wang, Allan J. Pantuck, Matthew B. Rettig · 2014 · Asian journal of urology
  88. Therapeutic Options in Metastatic Renal Cancer
    Themistoklis Ch. Bellos, Ioannis S. Manolitsis, Stamatios N. Katsimperis, Ioannis P. Kyriazis, Panagiotis A. Angelopoulos, Panagiotis N. Neofitou, Sotirios G. Kapsalos‐Dedes, Panagiotis K. Deligiannis, Lazaros I. Tzelves, Nikolaos A Kostakopoulos et al. · 2022 · Hellenic Urology
  89. Research Progress on First-Line Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
    家伟 赵 · 2024 · Advances in Clinical Medicine
  90. Optimisation de la distribution des chimiothérapies pour contourner la résistance liée au microenvironnement tumoral
    Olivier Trédan · 2009
  91. Rôle de BMP2 sur la différenciation vasculaire des cellules souches mésenchymateuses issues de la moëlle osseuse
    Karim Belmokhtar · 2011
  92. Role of VDAC1 hypoxic form, VDAC1-∆C, in the expression of primary cilia and tumor progression
    Lucilla Fabbri · 2019 · theses.fr (ABES)
  93. Évaluation de nouvelles thérapeutiques ciblées pour le traitement du chondrosarcome et de l'ostéosarcome
    Jennifer Perez · 2011
  94. Impact du ciblage du domaine de liaison de HIF-1α avec HIF-1β sur le paysage immunitaire du mélanome
    Audrey Lequeux · 2020 · theses.fr (ABES)
  95. Mécanismes moléculaires du contrôle de l'arborisation axonale par une régulation post-traductionnelle de la kinase LKB1
    Audrey Garcia · 2020 · theses.fr (ABES)
  96. Role of hypoxia and metabolism in the maturation of hemodialysis arteriovenous fistulas
    Nirvana Sadaghianloo · 2018
  97. Rôle et ciblage de HIF-2a dans les gliomes de haut-grade pédiatrique de la ligne médiane
    Quentin Fuchs · 2022 · theses.fr (ABES)
  98. BindingDB Entry 50022589: Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
    BindingDB · 2025 · UC San Diego
  99. BindingDB Entry 50015429: Potent Inhibition of HIF1α and p300 Interaction by a Constrained Peptide Derived from CITED2.
    BindingDB · 2023 · UC San Diego
  100. Tratamiento sistémico del carcinoma de células renales metastásico
    Glenn Scott Kroog, Robert John Motzer · 2008 · Clínicas urológicas de Norteamérica